Related Experiment Video
Updated: May 20, 2025
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Unveiling the paradigm shift: systemic treatment strategies in small, node-negative breast cancer
Mariana Carvalho Gouveia1, Mariana Scaranti2, Bruna Migliavacca Zucchetti2
1Department of Medical Oncology, DASA Oncology, 9 de Julho Hospital, São Paulo, Brazil. marianacgouveia@gmail.com.
Abstract:
The implementation of screening mammography has significantly altered the size distribution of breast tumors, with approximately 20% of newly diagnosed breast cancers measuring 10 mm or smaller with node-negative disease (T1aN0 and T1bN0). The management of these early-stage breast cancers remains a subject of debate. Historically, patients with T1aN0 and T1bN0 breast cancer have been excluded from adjuvant chemotherapy trials due to their excellent prognosis, with reported 10-year disease-specific survival rates exceeding 90%. However, the optimal treatment strategy for this subgroup of patients continues to be controversial, as the potential benefits of adjuvant chemotherapy must be carefully weighed against the risks of overtreatment. In this review, we summarize current evidence on outcomes and treatment strategies, highlight gaps in the literature, and provide future perspectives on the management of T1aN0 and T1bN0 breast cancer, according to immunohistochemical subtypes.
Insights
Screening mammography detects small, node-negative breast cancers (T1aN0, T1bN0). Optimal treatment, balancing chemotherapy benefits against overtreatment risks, remains debated for these early-stage cases.
Area of Science:
- Oncology
- Radiology
- Breast Cancer Research
Background:
- Screening mammography has led to earlier detection of breast cancers.
- A significant proportion of newly diagnosed breast cancers are now small (≤10 mm) and node-negative (T1aN0, T1bN0).
- These early-stage cancers historically had excellent prognoses, with >90% 10-year disease-specific survival.
Purpose of the Study:
- To review current evidence on the management of T1aN0 and T1bN0 breast cancer.
- To discuss the ongoing debate regarding adjuvant chemotherapy for these early-stage tumors.
- To identify gaps in the literature and suggest future research directions.
Main Methods:
- Literature review of existing studies and clinical trial data.
- Analysis of outcomes based on tumor size and nodal status.
- Consideration of immunohistochemical subtypes in treatment strategies.
Main Results:
- T1aN0 and T1bN0 breast cancers are increasingly diagnosed due to screening.
- These tumors generally have a favorable prognosis, leading to historical exclusion from chemotherapy trials.
- Controversy exists regarding the necessity and benefit of adjuvant chemotherapy versus the risk of overtreatment.
Conclusions:
- The management of small, node-negative breast cancers (T1aN0, T1bN0) requires careful consideration.
- Balancing the potential benefits of adjuvant chemotherapy against overtreatment risks is crucial.
- Further research, stratified by immunohistochemical subtypes, is needed to optimize treatment strategies.
More Related Videos
08:54Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...